Business Context and Reporting Period
This Form 8-K was filed by Marshall Edwards, Inc. (not Lite Strategy, Inc.) on June 4, 2012. The report details the announcement of results from a Phase I clinical trial for the company's lead drug candidate, ME-143, presented at the American Society of Clinical Oncology Annual Meeting.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial outcomes and does not contain financial statements.
Material Changes and Clinical Results
- Drug Candidate: ME-143, a next-generation NADH oxidase inhibitor.
- Trial Design: Open-label Phase I study initiated in September 2011 to evaluate safety, tolerability, and pharmacokinetics in patients with refractory solid tumors.
- Enrollment: 15 patients enrolled across escalating dose cohorts (2.5, 5, 10, and 20 mg/kg).
- Safety Profile: Generally well tolerated on a weekly schedule. One serious infusion reaction occurred at the highest dose level (20 mg/kg).
- Efficacy: Stable disease observed in one patient for more than 15 weeks. The maximum tolerated dose was defined as 20 mg/kg.
Outlook and Management Commentary
Management noted that the stable disease response in the ME-143 trial is comparable to Phase I studies of Phenoxodiol, the company's first-generation NADH oxidase inhibitor. The filing does not provide specific financial guidance, risk factors, or contingencies beyond the clinical data presented.
Investor Verification Checklist
- Verify the full text of the poster presentation available at the company's website.
- Confirm the specific nature of the serious infusion reaction at the 20 mg/kg dose level.
- Review subsequent filings for updates on Phase II trial initiation or regulatory status.
- Check the company's cash position in recent 10-Q or 10-K filings, as this 8-K does not disclose liquidity.